Status:
WITHDRAWN
Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
Oral supplementation of histidine in patients with cognitive dysfunction should increase brain anserine, carnosine and histamine levels which will result in improved cognition via numerous proven in v...
Detailed Description
The patients will be offered enrollment by sequential measures with odd numbers placed into the Control Group and even numbers in the Treatment Arm. One hundred patients will be enrolled in each arm. ...
Eligibility Criteria
Inclusion
- \>49 years
- Live at home currently
- Clinical Dementia Score of 3.0 or higher
Exclusion
- psychiatric
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06169826
Start Date
April 1 2025
End Date
April 1 2026
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States, 27157